- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- DU.4475 breast carcinoma
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 647 under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
ICC?- Verified
SB - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?L per million cells in 100 ?L staining volume or 5 ?L per 100 ?L of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
* Alexa Fluor? 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm.
Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.
View full statement regarding label licenses - Excitation Laser
- Red Laser (633 nm)
- Application Notes
Additional reported applications (for the revelant formats) include: immunofluorescence,?immunohistochemistry3, and spatial biology (IBEX)4,5.
- Additional Product Notes
Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
- Application References
(PubMed link indicates BioLegend citation) -
- Lammers R, et al. 2002. Exp. Hematol. 30:537.
- Schultz LD, et al. 2010. P. Natl. Acad. Sci. USA 107:13022. PubMed
- Human Protein Atlas http://www.proteinatlas.org/ENSG00000119888/antibody (IHC)
- Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
- Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
- Product Citations
-
- Sun L, et al. 2021. Cancer Cell. :. PubMed
- Meirelles K, et al. 2012. Proc Natl Acad Sci U S A. 109:2358. PubMed
- Pham K, et al. 2016. Am J Pathol. 186: 1537-1546. PubMed
- Qin XY, et al. 2020. Cell Death Dis. 0.504166667. PubMed
- Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
- Hendricks A, et al. 2021. Front Oncol. 11:646885. PubMed
- Ebisudani T, et al. 2021. Cell Reports. 35(10):109218. PubMed
- Kitajima S, et al. 2019. Cancer Discov. 9:34. PubMed
- Robertson N, et al. 2020. J Biol Chem. . PubMed
- Campisi M, et al. 2020. Front Immunol. 1.909722222. PubMed
- Csizmar CM, et al. 2019. J Am Chem Soc. 141:251. PubMed
- Hendricks A, et al. 2020. Cancers (Basel). 12:00. PubMed
- Rosenbluth JM, et al. 2020. Nat Commun. 11:1711. PubMed
- Liu T, et al. 2019. Oncol Lett. 18:2262. PubMed
- Stallcop LE, et al. 2018. Lab Chip. 18:451. PubMed
- Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
- Vanslambrouck JM, et al. 2022. Nat Commun. 13:5943. PubMed
- Zhou J, et al. 2011. J Vis Exp. 55: 3322. PubMed
- Robertson N, et al. 2020. J Biol Chem. 295:18436. PubMed
- Liu X, et al. 2021. iScience. 24(6):102551. PubMed
- Freire‐Pritchett P et al. 2017. eLife. 6 pii: e21926. PubMed
- Sun Q, et al. 2018. J Clin Invest. 128:531. PubMed
- Morris EJ, et al. 2020. Cell Rep. 30:3605. PubMed
- RRID
- AB_756086 (BioLegend Cat. No. 324212)
